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METHODS

Experimental Design and Procedures
Naive, mauritius, female cynomolgus monkeys (Macaca fascicularis) were provided by Charles River Laboratories (Houston, TX). Monkeys were screened and determined to be negative for Herpes B virus, simian retrovirus and simian immunodeficiency virus. The animals were individually caged and quarantined for 10 days prior to study initiation in accordance with standards set forth in The Guide for the Care and Use of Laboratory Animals (1996) .
Ten animals were screened for red blood cell (RBC) complement receptor-1 (CR1) receptor density, using a quantitative CR1 receptor assay, prior to study initiation. Six animals were identified for use in the study and randomly stratified into two treatment groups (test and control) based on CR1 receptor number and body weight. To block iodine uptake by the thyroid, all animals received supersaturated potassium iodide solution orally once daily from day -2 to day 2 (Ross et. al., 1985; Ferguson et.al., 1995) .
The animals were tranquilized with tiletamine (A.H. Robbins Co., 6 mg/kg intramuscularly) for initial blood collection, dose administration, and whole body gamma imaging. Tranquilization was performed with ketamine HCl (10 mg/kg intramuscularly) for subsequent blood collection and gamma imaging. Animals were also anesthetized with isoflurane inhalant (1-3%), delivered through a facemask, during the 5-minute gamma imaging procedures.
To slow absorption of the study agent and balance the timing of fluid collections, animals received a 25 mL/kg subcutaneous injection of Lactated Ringer's Solution prior to dosing and following the 8-hour and 24-hour sample collections. Table 1 . Gamma images of each animal were obtained at 5 minutes and at 1, 8, and 24 hours following treatment with the radiolabeled antibodies. Gamma images at 48 and 72 hours were obtained for the animals remaining in each treatment group.
Test and Control Materials
A 100-mg vial of lyophilized infliximab was reconstituted with 10 mL of USP sterile water for injection. The final protein concentration of 9.68 mg/mL was determined by absorption at 280 nm.
The test antibody (rhesus monkey anti-infliximab) and the control antibody (non-immune rhesus monkey IgG) were both purified by affinity chromatography using a liquid chromatography instrument (AKTA FPLC, Amersham Pharmacia). The test antibody was prepared by immunization of a cynomolgus monkey with infliximab every three weeks until a high titer antiserum specific to the variable region of infliximab was achieved. The control antibody was purified using a Protein G affinity chromatography column; the test antibody was purified using an infliximab affinity column. Affinity columns were equilibrated and loaded This article has not been copyedited and formatted. The final version may differ from this version. 125 NaI using the iodogen method (Fraker et. al., 1978) . The final 125 I-labeled rhesus monkey antiinfliximab IgG had a protein concentration of 1.39 mg/mL and a specific activity of 1.43 x 10 6 counts per minute (CPM)/µg (652 µCi/mg). The final 125 I-labeled non-immune rhesus monkey
IgG had a protein concentration of 1.31 mg/mL and a specific activity of 1.35 x 10 6 CPM/µg (616 µCi/mg based on 100% gamma counter efficiency).
Plasma Concentrations of Radiolabeled Antibody
The concentration of the radiolabeled antibodies was determined in plasma samples following trichloroacetic acid (TCA) precipitation. Briefly, 90 µL of serum was precipitated with 10 µL of 100% TCA. Following centrifugation, three 25-µL aliquots of the serum supernatant and the resultant protein pellet were analyzed on a Wallac 1470 Wizard gamma counter. The plasma concentrations of infliximab-specific (test) and non-specific (control) radiolabeled antibodies were reported by converting plasma TCA precipitable CPM to µg/mL equivalents of antibody.
High-Performance Liquid Chromatography Analysis of Plasma Samples
Ethylene diamine tetra-acetic acid (EDTA) plasma samples were thawed at room temperature and centrifuged; a 100-µL aliquot of the cleared plasma was dispensed into autosampler vials for analysis on a PerSeptive Biosystems Integral 100Q high-performance liquid chromatography (HPLC) column equipped with a Packard 500TR Series flow scintillation This article has not been copyedited and formatted. The final version may differ from this version. analyzer. The sample was separated on a 600 x 7.5-mm BioSep-SEC-S 3000 PEEK (Phenomenex) column using an isocratic 1X DPBS buffer. HPLC analysis was performed for all collected timepoints. The HPLC column was calibrated using molecular weight standards prior to test sample analysis, and least squares regression analysis was performed on the log of the molecular weight of the standard versus its retention time.
Plasma Concentrations of Infliximab
Plasma infliximab concentrations were determined with a sandwich ELISA format using two different, specific murine antibodies to quantify free infliximab concentrations relative to a standard curve (Maini et al., 1998) . Theoretically, due to the specificity of the murine antibodies, this assay could possibly detect IFX that was monovalently complexed by anti-IFX, but this is not supported by clinical data. Pharmacokinetic analysis to determine the mean maximum plasma concentration (C max ), half-life (t 1/2 α and t 1/2 β), area under the curve (AUC), clearance (CL) and volume of distribution (Vz) for the radiolabeled antibodies as well as for infliximab was completed with non-compartmental techniques using WinNonLin Professional V.3.3 (Pharsight Corp.).
Red Blood Cell Analysis for Radiolabeled Antibodies
To characterize whether the infliximab-test antibody complexes were being eliminated by binding to RBCs, we measured the amount of radioactivity bound to these cells over time for the two groups of animals. The total CPM in the packed RBCs from 200 µL of whole blood was determined for both test and control animal serum. EDTA tubes were immediately placed on ice following blood collection. An aliquot of the whole blood was layered onto an oil mixture (Ross et al 1985 , Ferguson et al 1995 .
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Gamma Imaging Studies
Gamma images for each animal were obtained at 5 minutes and 1, 8, and 24 hours following treatment with radiolabeled antibody. Gamma imaging at 48 and 72 hours was also performed as appropriate for the treatment group. The anesthetized animals were placed in a prone position on the collimator for imaging studies. The field of view contained the region from the neck to lower abdomen of the animal. Following necropsy, gamma images of the intact liver, lungs, kidney, and spleen were also acquired. Activity was determined with a Technicare 410/520 gamma camera, equipped with a large field of view and a medium energy collimator attached to a nuclear medicine computer (Technicare 560). Counts were performed over a 5-minute interval.
Histology
Immediately following imaging, sections from the liver, lungs, kidney, and spleen were fixed in 10% neutral buffered formalin. The tissues were trimmed, embedded, and sectioned.
Slides were stained with hematoxylin and eosin. Slides were read and interpreted by a veterinary pathologist.
Immunohistochemistry
Two, approximately 1.0-cm 2 sections were collected from the liver, lungs, kidney, and spleen of each animal. The sections were placed in OCT media and stored at -70°C. Ten slides from each piece of tissue (5 µM thick) were prepared. Immunoperoxidase staining (secondary antibody) of tissue sections was performed using anti-infliximab antibody C248 at a dilution of 1:10 for one hour and antibody C465, the parental murine antibody from which infliximab was This article has not been copyedited and formatted. The final version may differ from this version. 14 derived, at a dilution of 1:100 for 1.5 hours. Endogenous peroxidase was blocked with methanol for 3 minutes, and non-specific background was blocked by incubating sections for 5 minutes in normal swine serum.
Total Complement Hemolytic Activity
The complement system represents a group of over 20 serum proteins that may be activated by the presence of immune complexes. Total complement hemolytic activity (CH50) was measured in a standard assay using antibody-sensitized sheep RBCs as substrate (Taylor et. al., 1997) .
RESULTS
Plasma Concentrations of Radiolabeled Antibody
The mean plasma concentrations of infliximab-specific (test) and non-specific (control) radiolabeled antibodies over time showed low coefficients of variation for both groups at each time point, reflecting the consistency of dosing across groups as well as the in vivo processing.
Although comparable amounts of 125 I test and control antibodies were administered, notably lower serum concentrations of the immune (test) antibodies were observed relative to the control antibodies at the 5-minute collection point (11.7 µg/mL and 15.3 µg/mL, respectively). The serum concentration of the test antibody decreased more rapidly than that of the control antibody through the first 8 hours and then closely paralleled the level of control antibody through 72
hours. The antibody measurements were based upon the specific radioactivity of the test and control antibodies; therefore, the calculated concentration of these antibodies could reflect a detection of free antibody and/or an antibody-immune complex with infliximab.
High-Performance Liquid Chromatography Analysis of Plasma Samples
HPLC analyses were performed to determine whether immune complexes formed between infliximab and the test or control antibodies. The plasma HPLC radioactivity traces for all three control animals at all time points demonstrated an IgG monomer peak eluting at 16 minutes and a small free 125 I peak at 24 minutes retention time. Overlaid traces from a representative control monkey 2101 at 5 minutes and 24 and 48 hours are shown in Figure 1 The plasma HPLC radioactivity retention profiles were similar for the three test animals and distinct from the profiles observed for the control animals. Representative profiles from test monkey 1101 for plasma collected at 5 minutes and 24 and 48 hours are shown in Figure 1 (bottom panel 
Plasma Concentrations of Infliximab
Prior to administration of the radiolabeled antibodies, the mean plasma infliximab concentration was approximately 8 µ g/mL lower for the animals in the test group receiving the immune antibody than for the control animals, and this relative difference was maintained for 8 hours following receipt of the radiolabeled antibodies.
Since the duration of PK sample collection was variable (24, 48, or 72 hours) for each of the three animals in each treatment group, the derived pharmacokinetic data analysis for the radiolabeled antibodies as well as for infliximab was performed using the average plasma This article has not been copyedited and formatted. The final version may differ from this version. Table 2 .
Red Blood Cell Analysis for Radiolabeled Antibodies
Elimination of infliximab antibody complexes via RBCs, as measured by RBC-bound radioactivity for test and control groups, is shown in Figure 2 
CR1 Quantitation by Radioimmunoassay and Flow Cytometry
To evaluate whether CR1 receptors were being stripped from the RBCs as a result of immune complex binding and clearance, RBC CR1 receptor analyses were performed using both 
Gamma Imaging Studies
Gamma images of each animal were obtained at 5 minutes; 1, 8, and 24 hours; and at the time of necropsy. Gamma images for a representative test and control animal at 24 hours are shown in Figure 4 . The test animals had a higher concentration of radioactivity in the liver, while the radioactivity in the control animals appeared to be distributed throughout the blood pool, with the highest concentration of radioactivity observed in the heart area. Following necropsy at 24, 48, and 72 hours, gamma images of the excised intact liver, lungs, kidney, and spleen were obtained for each animal. The radioactivity of each organ, as a proportion of the whole body CPM at the time of necropsy, was determined. The mean percentage of total radioactivity in the lung, liver, spleen, and kidney for the test group was 2.2%, 8.1%, 0.6%, and 2.0%, respectively.
Respective percentages for the control group were 3.3%, 6.6%, 0.4%, and 1.0%. There was a significantly higher percentage of counts for the test group compared with the control group for the liver (p=0.032) and the kidneys (p=0.010).
Histology
Histology slides of the lung, liver, kidney, and spleen were prepared from each animal at the time of necropsy and interpreted by a licensed veterinary pathologist. There were no reported macroscopic or microscopic findings from any of the examined organs in either treatment group.
Immunohistochemically, infliximab was detected using a specific monoclonal antibody in the cytoplasm in the liver Kupffer cells, kidney endothelial cells, and the reticular mononuclear cells in the germinal center of B-cell follicles in the white pulp of the spleen in all test animals at all time points. There was some staining in the spleen of the control animal necropsied at 24
hours, but to a lesser extent than the test animals. Anti-infliximab IgG was detected in This article has not been copyedited and formatted. The final version may differ from this version. Figure 5 . Figure 6 shows the mean CH50 levels (U/mL) for the test and control groups at -40 and 30 minutes and 3, 24, 48, and 72 hours. There was no difference in the mean CH50 level between test and control groups prior to initiation of treatment (p=0.832). Following administration of radiolabeled antibody, the mean CH50 level in the test group remained lower than in the control group until the levels equilibrated at 72 hours. In the test group, there was a marked decrease in the CH50 level at 30 minutes; however, this was not significantly different than in the control group (p=0.232). The overall gradual increase in CH50 values for both the test and control groups is likely a result of stress on the animals due to anesthesia, handling, and repeated blood sampling.
Complement System Concentration: CH50 Levels
Hematology and Serum Chemisty
The results of hematology and serum chemistry analyses were comparable for the test and control treatment groups and within normal reference ranges (data not shown). However, Figure 7 shows there was a significant mean increase in serum glucose levels, compared with pretreatment values, for the test group compared with the control group (52.7 and 13.7 mg/dL, respectively p=0.025).
This article has not been copyedited and formatted. The final version may differ from this version. pinocytized depending on whether they are particulate or soluble (Daeron, 1997; Aderem et al., 1999) .
In this study, the RBCs appeared to play only a limited role in elimination of these immune complexes, and it did not appear that CR1 participated in the mechanism by which the complexes were eliminated. The peak binding activity of 5.2% in the test group occurred at 8
hours. This percentage is comparable to results of a recent study in which immune complexes were identified that were very poor at complement fixation (Davies et al., 2002) . In fact, complexation of the antibodies to the therapeutic antigen (antibody) can promote binding to the low affinity FcγRII or FcγRIII receptors (Daeron, 1997) . Kupffer cells and liver endothelial cells both possess FcγRII and FcγRIII receptors (Muro et al., 1993; Ahmed et al., 1995; Lovdal et al., 2000) . Once the immune complex has been engaged by the Fcγ receptors, the complexes would be internalized and travel from the endosome to the lysosome (Lovdal et al., 2000) , where the complexes would be expected to be enzymatically digested.
Gamma imaging showed a higher proportion of the total radioactivity detected in the excised liver and kidney from the animals in the test group compared with those in the control group. In addition, the gamma imaging results were confirmed immunohistochemically since both infliximab and anti-infliximab IgG were independently detected in the liver and kidneys as well as in the spleen of the test animals. These results are consistent with immune complexes of infliximab and anti-infliximab being efficiently taken up by the mononuclear phagocytic system in the liver, followed by degradation and excretion of radio-iodinated species in the urine This article has not been copyedited and formatted. The final version may differ from this version. (Johansson et al., 2002) . The spleen involvement is not as clear but perhaps suggests immune surveillance.
The increase in serum glucose levels, compared with pretreatment values, for the test group compared with the control group may be explained by the release of prostaglandins from
Kupffer cells, which have been shown to increase the level of hepatic glycogenolysis (conversion of glycogen into glucose) following immune complex stimulation (Hespeling et al., 1995) .
However, these trends were not observed in a recent human clinical study of 1049 patients with early RA in which 67 subjects tested positive for antibodies to infliximab. Urine glucose test results were available for 63 of these subjects at 30 weeks following the initiation of infliximab treatment and all results were within normal reference ranges (data on file).
Immune complexes formed between a biotherapeutic agent and either neutralizing or non-neutralizing antibodies may be undetectable because of rapid in vivo clearance. In this study,
we have shown that immune complexes with a therapeutic monoclonal antibody were rapidly and safely eliminated in a monkey model.
These data indicate that it may be difficult to measure antibodies in the presence of excess biotherapeutic protein because the immune complexes are eliminated fairly rapidly. A variety of factors will affect the detection of the immune antibodies in the presence of excess therapeutic monoclonal antibody including the concentration, affinity, and rate of production of the immune antibody, the dosing and pharmacokinetic profile of the therapeutic monoclonal antibody, the assay sensitivity for the immune antibody, and the sampling schedule. It appears This article has not been copyedited and formatted. The final version may differ from this version. 
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